Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone

Journal of Neurotrauma

Volumn 29, Issue 10, 2012, Pages 1898-1907

  Olsen, Adam S ^a,b   Sozda, Christopher N ^a,b   Cheng, Jeffrey P ^a,b   Hoffman, Ann N ^a,b   Kline, Anthony E ^a,b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

5 HT1A receptor agonist; behavioral outcome; controlled cortical impact; functional recovery; hippocampus; learning and memory; Morris water maze; traumatic brain injury

Indexed keywords

BUSPIRONE; ISOFLURANE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN CORTEX LESION; CELL SURVIVAL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HISTOLOGY; LEARNING; LIGHT; MALE; MAZE TEST; MOTOR PERFORMANCE; NONHUMAN; RAT; SHAM PROCEDURE; SPATIAL MEMORY; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; BUSPIRONE; CHRONIC DISEASE; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAPERITONEAL; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84859737835     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2012.2358     Document Type: Article

References (63)

1. Albert, P.R., and Lemonde, S. (2004). 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist 10, 575-593.
2. Alessandri, B., Tsuchid, E., and Bullock, R.M. (1999). The neuroprotective effect of a new serotonin receptor agonist, BAY x3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res. 845, 232-235.
3. Bales, J.W., Wagner, A.K., Kline, A.E., and Dixon, C.E. (2009). Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis. Neurosci. Biobehav. Rev. 33, 981-1003.
4. Baños, J.H., Novack, T.A., Brunner, R., Renfroe, S., Lin, H.Y., and Meythaler, J. (2010). Impact of early administration of sertraline on cognitive and behavioral recovery in the first year after moderate to severe traumatic brain injury. J. Head Trauma Rehabil. 25, 357-361.
5. Barnes, N.M., and Sharp, T. (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38, 1083-1152.
6. Binder, L. (1986). Persistent symptoms after mild head injury: A review of the postconcussive syndrome. J. Clin. Exp. Neuropsychol. 8 323-346.
7. Cheng, J.P., Aslam, H.A., Hoffman, A.N., Zafonte, R.D., and Kline, A.E. (2007). The neurobehavioral benefit conferred by single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window. Neurosci. Lett. 416 165-168.
8. Cheng, J.P., Hoffman, A.N., Zafonte, R.D., and Kline, A.E. 2008). A delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learning. Behav. Brain Res. 194, 79-85.
9. Chew, E., and Zafonte, R.D. (2009). Pharmacological management of neurobehavioral disorders following traumatic brain injury-a state-of-the-art review. J. Rehabil Res. Dev. 46, 851-878.
10. Coop, C.F., and McNaughton, N. (1991). Buspirone affects hippocampal rhythmical slow activity through serotonin1A rather than dopamine D2 receptors. Neuroscience 40, 169-174.
11. De Vry, J., and Jentzsch, K.R. (1998). Discriminative stimulus properties of the 5-HT1A receptor agonist BAY x 3702 in the rat. Eur. J. Pharmacol. 357, 1-8.
12. De Vry, J., Dietrich, H., Glaser, T., Heine, H.-G., Horváth, E., Jork, R., Maertins, T., Mauler, F., Opitz, W., Scherling, D., Schohe-Loop, R., and Schwarz, T. (1997). BAY x 3702. Drugs Future 22, 341-349.
13. De Vry, J., Schohe-Loop, R., Heine, H.-G., Greuel, J.M., Mauler, F., Schmidt, B., Sommermeyer, H., and Glaser, T. (1998). Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine 1A receptor agonist. J. Pharmacol. Exp. Ther. 284, 1082-1094.
14. Dixon, C.E., Kraus, M.F., Kline, A.E., Ma, X., Ya, H.Q., Griffith, R.G., Wolfson, B.M., and Marion, D.W. (1999). Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. Restor. Neurol. Neurosci. 14, 285-294.
15. Dixon, C.E., Ma, X., and Marion, D.W. (1997). Effects of CDPcholinetreatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J. Neurotrauma 14, 161-169.
16. Faul, M., Xu, L., Wald, M.M., and Coronado, V.G. (2010). Traumatic brain injury in the United States: emergency department visits, hospitalizations and deaths 2002-2006. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control.
17. Feeney, D.M., Gonzalez, A., and Law, W.A. (1982). Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 217, 855-857.
18. Garcia, A.N., Shah, M.A. Dixon, C.E., Wagner, A.K., and Kline, A.E. (2011). Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation. PMR 3, S18-S27.
19. Goldstein, M. (1990). Traumatic brain injury: a silent epidemic. Ann. Neurol. 27, 327.
20. Hamm, R.J., Dixon, C.E., Gbadebo, D.M., Singha, A.K., Jenkins, L.W., Lyeth, B.G., and Hayes, R.L. (1992). Cognitive deficits following traumatic brain injury produced by controlled cortical impact. J. Neurotrauma 9, 11-20.
21. Harkany, T., Mulder, J., Horvath, K.M., Keijser, J., Van Der Meeberg, E.K., Nyakas, C., and Luiten, P.G.M. (2001). Oral post-lesion administration of the 5-HT1A receptor agonist repinotan hydrochloride (BAY X 3702) attenuates NMDAinduced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience 108, 629-642.
22. Hoffman, A.N., Cheng, J.P., Zafonte, R.D., and Kline, A.E. (2008). Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits. Life Sci. 83, 602-607.
23. Horneman, G., and Emanuelson, I. (2009). Cognitive outcome in children and young adultswho sustained a severe andmoderate traumatic brain injury 10 years earlier. Brain Inj. 23, 907-914.
24. Kline, A.E., Hoffman, A.N., Cheng, J.P., Zafonte, R.D., and Massucci, J.L. (2008). Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. Neurosci. Lett. 448, 263-267.
25. Kline, A.E., Massucci, J.L., Dixon, C.E., Zafonte, R.D., and Bolinger, B.D. (2004a). The therapeutic efficacy conferred by the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) after experimental traumatic brain injury is not mediated by concomitant hypothermia. J. Neurotrauma 21, 175-185.
26. Kline, A.E., Massucci, J.L., Marion, D.W., and Dixon, C.E. (2002a). Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. J. Neurotrauma 19, 415-425.
27. Kline, A.E., Massucci, J.L., Ma, X., Zafonte, R.D., and Dixon, C.E. (2004b). Bromocriptine reduces lipid peroxidation and enhances spatial learning and hippocampal neuron survival in a rodent model of focal brain trauma. J. Neurotrauma 21 1712-1722.
28. Kline, A.E. , Massucci, J.L., Zafonte, R.D., Dixon, C.E., DeFeo, J.R., and Rogers, E.H. (2007a). Differential effects of single versus multiple administrations of haloperidol and risperidone on functional outcome after experimental traumatic brain trauma. Crit. Care Med. 35, 919-924.
29. Kline, A.E., McAloon, R.L., Henderson, K.A., Bansal, U.K., Ganti, B.M., Ahmed, R.H., Gibbs, R.B., and Sozda, C.N. (2010). Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury. J. Neurotrauma 27, 2021-2032.
30. Kline, A.E. , Wagner, A.K., Westergom, B.P., Malena, R.R., Zafonte, R.D., Olsen, A.S., Sozda, C.N., Luthra, P., Panda, M., Cheng, J.P., and Aslam, H.A. (2007b). Acute treatment with the 5-HT1A receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma. Behav. Brain Res. 177, 186-194.
31. Kline, A.E., Yu, J., Horváth, E., Marion, D.W., and Dixon, C.E. (2001). The selective 5-HT1A receptor agonist repinotan HC attenuates histopathology and spatial learning deficits following traumatic brain injury in rats. Neuroscience 106, 547-555.
32. Kline, A.E., Yu, J., Massucci, J.L., Zafonte, R.D., and Dixon, C.E. (2002b). Protective effects of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n- propylamino)tetralin (8-OH-DPAT) against traumatic brain injury-induced cognitive deficits and neuropathology in adult male rats. Neurosci. Lett. 333, 179-182.
33. Koen, N., and Stein, D.J. (2011), Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin. Neurosci. 13, 423-437.
34. Kokiko, O.N., and Hamm, R.J. (2007). A review of pharmacological treatments used in experimental models of traumatic brain injury. Brain Inj. 21, 259-274.
35. Kreiss, D.S., and Lucki, I. (1992). Desensitization of 5-HT1A autoreceptors by chronic administration of 8-OH-DPAT. Neuropharmacology 10, 1073-1076.
36. Lüttgen, M., Elvander, E., Madjid, N., and Ögren, S.O. (2005). Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat. Neuropharmacology 48, 830-852.
37. Lyeth, B.G., Jenkins, L.W., Hamm, R.J., Dixon, C.E., Phillips, L.L., Clifton, G.L., Young, H.F., and Hayes, R.L. (1990). Prolonged memory impairment in the absence of hippocampal cell death following traumatic brain injury in the rat. Brain Res. 526, 249-258.
38. Matter, A.M., Folweiler, K.A., Curatolo, L.M., and Kline, A.E. (2011). Temporal effects of environmental enrichment-mediated functional improvement after experimental traumatic brain injuryin rats. Neurorehabil. Neural Repair 25, 558-564.
39. Max, W., Mackenzie, E.J., and Rice, D.P. (1991). Head injuries: costs and consequences. J. Head Trauma Rehabil. 6, 76-91.
40. McDowell, S., Whyte, J., and D'Esposito, M. (1998). Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 121, 1155-1164.
41. McMillen, B.A., Matthews, R.T., Sanghera, M.K., Shepard, P.D., and German, D.C. (1983). Dopamine receptor antagonism by the novel anti-anxiety drug, buspirone. J. Neurosci. 3, 733-738.
42. Meneses, A., and Perez-Garcia, G. (2007). 5-HT(1A) receptors and memory. Neurosci. Biobehav. Rev. 31, 705-727.
43. Meneses, A. (1999). 5-HT system and cognition. Neurosci. Biobehav. Rev. 23, 1111-1125.
44. Meneses, A. (2007). Stimulation of 5-HT1A, 5-HT1B, 5-HT2A/2C, 5-HT3 and 5-HT4 receptors or 5-HT uptake inhibition: short-and long-term memory. Behav. Brain Res. 184, 81-90.
45. Millis, S.R., Rosenthal, M., Novack, T.A., Sherer, M., Nick, T.G., Kreutzer, J.S., High, W.M. Jr., and Ricker, J.H. (2001). Longterm neuropsychological outcome after traumatic brain injury. J. Head Trauma Rehabil. 16, 343-355.
46. Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Meth. 11, 47-60.
47. Parton, A., Coulthard, E., and Husain, M. (2005). Neuropharmacological modulation of cognitive deficits after brain damage. Curr. Opin. Neurol. 18, 675-680.
48. Prehn, J.H., Backhauss, C., Karkoutly, C., Nuglisch, J., Peruche, B., Rossberg, C., and Krieglstein, J. (1991). Neuroprotective properties of 5-HT1A receptor agonists in rodent models of focal and global cerebral ischemia. Eur. J. Pharmacol. 203, 213-222.
49. Prehn, J.H., Welsch, M., Backhauss, C., Nuglisch, J., Ausmeier, F., Karkoutly, C., and Krieglstein, J. (1993). Effects of serotonergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia. Brain Res. 630 10-20.
50. Sakaue, M., Somboonthum, P., Nishihara, B., Koyama, Y., Hashimoto, H,. Baba, A., and Matsuda, T. (2000). Postsynaptic 5-hydroxytryptamine (1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br. J. Pharmacol. 129, 1029-1034.
51. Scheff, S.W., Baldwin, S.A., Brown, R.W., and Kraemer, P.J. (1997). Morris water maze deficits in rats following traumatic brain injury: lateral controlled cortical impact. J. Neurotrauma 14, 615-627.
52. Selassie, A.W., Zaloshnja, E., Langlois, J.A., Miller, T., Jones, P., and Steiner, C. (2008). Incidence of long-term disability following traumatic brain injury hospitalization, United States, 2003. J. Head Trauma Rehabil. 23, 123-131.
53. Semkova, I., Wolz, P., and Krieglstein, J. (1998). Neuroprotective effect of 5-HT1A receptor agonist, Bay x 3702, demonstrated in vitro and in vivo. Eur. J. Pharmacol. 359, 251-260.
54. Sosin, D.M., Sniezek, J.E., and Waxweiler, R.J. (1995). Trends in death associated with traumatic brain injury, 1979 through 1992. JAMA 273, 1778-1780.
55. Sozda, C.N., Hoffman, A.N., Olsen, A.S., Cheng, J.P., Zafonte, R.D., and Kline, A.E. (2010). Empirical comparison of typical and atypical environmental enrichment paradigms on functional and histological outcome after experimental traumatic brain injury. J. Neurotrauma 27, 1047-1057.
56. Summers, C.R., Ivins, B., and Schwab, K.A. (2009). Traumatic brain injury in the United States: an epidemiologic overview. Mt. Sinai J. Med. 76, 105-110.
57. Sutton, R.L., and Feeney, D.M. (1992). a-Noradrenergic agonists and antagonists affect recovery and maintenance of beamwalking ability after sensorimotor cortex ablation in the rat. Restor. Neurol. Neurosci. 4, 1-11.
58. Temple, M.D., and Hamm, R.J. (1996). Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Res. 741, 246-251.
59. Verbois, S.L., Hopkins, D.M., Scheff, S.W., and Pauly, J.R. (2003). Chronic intermittent nicotine administration attenuates traumatic brain injury-induced cognitive dysfunction. Neuroscience 119, 1199-1208.
60. Wang, Y., Neumann, M., Hansen, K., Hong, S.M., Kim, S., Noble-Haeusslein, L.J., and Liu, J. (2011). Fluoxetine increases hippocampal neurogenesis and induces epigenetic factors but does not improve functional recovery after traumatic brain injury. J. Neurotrauma 28, 259-268.
61. Wheaton, P., Mathias, J.L., and Vink, R. (2009). Impact of early pharmacotherapy treatment on cognitive and behavioral outcome after traumatic brain injury in adults: a meta-analysis. J. Clin. Psychopharmacol. 29, 468-477.
62. Wilson, M.S., Gibson, C.J., and Hamm, R.J. (2003). Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats. Am. J. Phys. Med. Rehabil. 82, 871-879.
63. Wilson, M.S., and Hamm, R.J. (2002). Effects of fluoxetine on the5-HT1A receptor and recovery of cognitive function after traumatic brain injury in rats. Am. J. Phys. Med. Rehabil. 81,364-372.